75
Participants
Start Date
September 30, 2013
Primary Completion Date
August 31, 2015
Study Completion Date
August 21, 2018
Placebo Viaskin® Patch
Placebo (e.g., no peanut) patch in an epicutaneous application for 24 hours every 24 hours.
Low-dose DBV712 Viaskin® Patch
100 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
High-dose DBV712 Viaskin® Patch
250 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
Icahn School of Medicine at Mount Sinai, New York
The Johns Hopkins University, Baltimore
University of North Carolina at Chapel Hill School of Medicine, Chapel Hill
Arkansas Children's Hospital, Little Rock
National Jewish Health, Denver
Collaborators (1)
Consortium of Food Allergy Research
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH